Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.01
Nov 20 • 3:15 PM ET Dollar change-0.05 Percentage change(-4.71%)
Index
-
Market Cap
38.61M
Enterprise Value
33.78M
Income
-25.18M
Sales
0.10M
Book/sh
1.88
Cash/sh
0.13
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
8
IPO
Dec 17, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
386.13
P/B
0.54
P/C
7.80
P/FCF
-
EV/EBITDA
-
EV/Sales
337.83
Quick Ratio
2.78
Current Ratio
2.78
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-0.89
EPS next Y
-0.71
EPS next Q
-0.15
EPS this Y
87.87%
EPS next Y
17.92%
EPS next 5Y
52.79%
EPS past 3/5Y
36.34% 25.53%
Sales past 3/5Y
- -
EPS Y/Y TTM
96.43%
Sales Y/Y TTM
-
EPS Q/Q
98.26%
Sales Q/Q
-
Insider Own
74.09%
Insider Trans
0.00%
Inst Own
10.46%
Inst Trans
0.96%
ROA
-30.05%
ROE
-35.58%
ROIC
-39.23%
Gross Margin
-54.70%
Oper. Margin
-18672.57%
Profit Margin
-25179.61%
SMA20
-11.24%
SMA50
-22.62%
SMA200
-45.02%
Trades
Shs Outstand
34.13M
Shs Float
9.91M
52W High
7.04 -85.66%
52W Low
0.90 12.11%
Volatility
12.03% 12.81%
ATR (14)
0.14
RSI (14)
35.81
Beta
2.16
Rel Volume
1.69
Avg Volume
89.11K
Volume
136,970
Perf Week
-9.00%
Perf Month
-9.81%
Perf Quarter
-60.54%
Perf Half Y
-43.57%
Perf YTD
-75.72%
Perf Year
-83.02%
Perf 3Y
-94.48%
Perf 5Y
-99.27%
Perf 10Y
-
Prev Close
1.06
Price
1.01
Change %
-4.71%
Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.
Chairman & CEOMr. Gregory Duncan
CFOMs. Angela Walsh
Ph.D.Dr. R. Michael Gendreau M.D.
Founder & Member of Scientific Advisory BoardDr. William L. Pridgen M.D.
Senior Vice President of OperationsMr. Ralph D. Grosswald M.P.H.